Though further investigations are needed, these studies support the possibility of using TSPAN7, AKR1C1/2, and CYR61 as biomarkers for resistance and that knockdown or inhibition of these genes may prevent or reduce platinum chemoresistance in bladder cancer. Here, AKR1C1 is linked to urinary bladder carcinoma.